LHX:NYSEL3Harris Technologies, Inc. Analysis

L3Harris (LHX) is trading at $289.38, which sits below its 20‑day ($301.53) and 50‑day ($309.82) simple moving averages, signaling short‑term weakness. The MACD line remains in bearish territory (-6.42) and is under its signal line, while the RSI at 40 suggests momentum is fading but not yet oversold. Volume has been increasing, providing some support for a bounce toward the near‑term support level of $282.41. However, the price is still well above the DCF‑derived fair value of $190.65, indicating the stock is currently overvalued on a fundamentals basis.
On the fundamental side, revenue grew modestly 1.9% YoY to $12.86 B and operating margins hover around 9.7%, with a forward PE of 21 versus a trailing PE of 31, reflecting earnings acceleration. The company recently secured a U.S. Army contract worth up to $106 million for its Vampire counter‑UAS system, adding a tangible catalyst for future top‑line growth. Dividend sustainability looks solid, with a 1.73% yield and a payout ratio near 53% supported by strong operating cash flow. Analyst consensus remains bullish, with a median price target of $390 and a “Buy” recommendation. Given the defensive nature of the aerospace & defense sector, low beta, and expanding defense budgets, the medium‑ to long‑term outlook remains positive despite short‑term technical pressure. The stock’s beta of roughly 0.35 suggests limited sensitivity to broader market swings, while 30‑day volatility of 31% signals higher price swings that traders should watch. The balance sheet shows high debt ($7.9 B) but ample cash and a manageable debt‑to‑equity of 34.6, which the company can service given its cash flow generation.